^
Association details:
| Biomarker: | FLT3‐ITD + NPM1 mutation |
|---|---|
| Cancer: | Acute Myelogenous Leukemia |
| Drug: | entospletinib (GS-9973) (SYK inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
2759 Entospletinib (ENTO) in Combination with Cytarabine (Ara-C) and Daunorubicin (DNR) in Newly Diagnosed (ND) Adult Patients with NPM1-Mutated and FLT3-ITD Wild-Type Acute Myeloid Leukemia (AML) Is Associated with Good Response and Survival: A Phase 2 Sub-Study of the Beat AML Master Trial
Published date:
11/03/2022
Excerpt:
Median time on Tx was 129 days (range: 12-613). CCR rate with up to 2 cycles of IND Tx was 20/27 (74%); with CR of 18/27 or 67% (3 CRMRD-, 5 CRDMRD+, and 10 CRMRDUNK), CRh and CRi (1/27 or 4% each) (Table 2). Overall CR+CRh+CRi rate was 78%. Median duration of response was 15.7 months...ENTO with 7+3 IND and Ara-C CON therapy demonstrated a high CCR rate and encouraging mOS in ND NPM1+/FLT3-ITD- AML pts up to age 75.
Secondary therapy:
cytarabine + daunorubicin
DOI:
https://doi.org/10.1182/blood-2022-167316
Trial ID:
